ArticleEClinicalMedicine2019

Considering sex-specific adverse drug reactions should be a priority in pharmacovigilance and pharmacoepidemiological studies.

Maryse Lapeyre-MestrePubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.